IGI, Abbvie team up to advance myeloma treatment ISB 2001
Ichnos Glenmark Innovation (IGI) is partnering with Abbvie to advance the development of ISB 2001, a multiple myeloma treatment candidate that’s now in…
News
AML treatment ICT01 granted FDA’s orphan drug status
ICT01, an immune-modulating therapy being developed by Imcheck Therapeutics for acute myeloid leukemia (AML), has been granted orphan drug status by the U.S. Food…
Quemliclustat named orphan drug by FDA for pancreatic cancer
Quemliclustat has been granted an orphan drug designation in the U.S. as a potential treatment for pancreatic cancer. The U.S. Food and Drug Administration…
FDA names MB-101 US orphan drug for certain types of glioma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed by Mustang Bio to…
Approval sought of relacorilant for platinum-resistant ovarian cancer
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
FDA OKs label changes to boost CAR T-cell therapy use for cancer
The U.S. Food and Drug Administration (FDA) has approved label updates for two Bristol Myers Squibb (BMS) CAR T-cell therapies, both for the treatment…
Oral Inqovi, venetoclax for acute myeloid leukemia to be reviewed
The U.S. Food and Drug Administration (FDA) has agreed to review an application for oral Inqovi (decitabine and cedazuridine) in combination with oral venetoclax for…
Daraxonrasib granted breakthrough designation for pancreatic cancer
Daraxonrasib, Revolution Medicines’ RAS inhibitor candidate for the treatment of people with advanced, or metastatic, pancreatic cancer with KRAS G12 mutations, has been…
Stories being shared in honor of Glioblastoma Awareness Day
July 16 marks Glioblastoma Awareness Day (GBM Day), an annual observance dedicated to raising awareness about the rare and aggressive form of brain cancer, promoting…
CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
